Q2 EPS Estimate for Applied Therapeutics Cut by Analyst

Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) - Equities research analysts at William Blair decreased their Q2 2025 earnings per share (EPS) estimates for Applied Therapeutics in a note issued to investors on Tuesday, October 22nd. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings per share of ($0.11) for the quarter, down from their previous forecast of ($0.10). William Blair has a "Strong-Buy" rating on the stock. The consensus estimate for Applied Therapeutics' current full-year earnings is ($0.48) per share. William Blair also issued estimates for Applied Therapeutics' Q3 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.36) EPS.

Other research analysts also recently issued research reports about the stock. Leerink Partners upped their price objective on shares of Applied Therapeutics from $11.00 to $14.00 and gave the stock an "outperform" rating in a report on Thursday, September 19th. Citigroup lifted their price target on shares of Applied Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $12.00 target price on shares of Applied Therapeutics in a research report on Wednesday, July 17th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $12.50.

Applied Therapeutics Trading Down 0.6 %

APLT stock traded down $0.05 during mid-day trading on Thursday, hitting $8.92. The stock had a trading volume of 1,554,214 shares, compared to its average volume of 1,835,387. The company has a fifty day moving average of $7.08 and a 200 day moving average of $5.65. Applied Therapeutics has a 1-year low of $1.79 and a 1-year high of $9.39. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.88 and a beta of 2.04.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $10.00 million.

Insider Buying and Selling at Applied Therapeutics

In other news, CEO Shoshana Shendelman sold 119,591 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $5.93, for a total transaction of $709,174.63. Following the completion of the sale, the chief executive officer now owns 4,690,839 shares of the company's stock, valued at $27,816,675.27. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Applied Therapeutics in the 2nd quarter valued at approximately $920,000. Bank of New York Mellon Corp bought a new position in shares of Applied Therapeutics during the second quarter worth $1,325,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Applied Therapeutics by 17.1% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company's stock worth $10,676,000 after acquiring an additional 333,278 shares during the period. Peregrine Capital Management LLC acquired a new position in Applied Therapeutics during the 2nd quarter worth about $3,414,000. Finally, Algert Global LLC purchased a new position in Applied Therapeutics in the second quarter worth $110,000. Institutional investors own 98.31% of the company's stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.